Paternal Antiseizure Rx Use at Conception Does Not Pose Risk to Offspring
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 23, 2024 -- Limited data indicate that paternal exposure to antiseizure medications (ASMs) at conception is unlikely to pose any major risk for adverse outcomes for offspring, according to a review published online Sept. 17 in the Journal of Neurology, Neurosurgery & Psychiatry.
Eliza Honybun, from the University of Melbourne in Australia, and colleagues conducted a systematic review to assess neurodevelopmental and anatomical outcomes in offspring born to fathers taking ASMs at the time of conception. Twenty-six studies underwent full-text review; 10 met the eligibility criteria for inclusion.
The researchers found limited evidence was available, and no clear evidence was found for an adverse impact of paternal ASM use on offspring outcomes. The few isolated adverse findings were not seen in other studies. A meta-analysis was prevented by several methodological limitations, including failure to report outcomes separately for each individual ASM, heterogeneity in measurement and outcome reporting, and small numbers of monotherapy exposures.
"While the findings summarized in our systematic review are overall reassuring for males taking ASMs, including valproate, it is clear that the potential reproductive implications of ASM exposure in males remain an underinvestigated area of research that should be prioritized over the next decade," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
AAP Updates Recommendations for Adolescent Contraceptive Counseling
MONDAY, June 16, 2025 -- In a policy statement issued by the American Academy of Pediatrics and published online June 16 in Pediatrics, updated recommendations are presented for...
Epilepsy More Common With Frontotemporal Dementia
TUESDAY, June 10, 2025 -- Epilepsy is more common among those with frontotemporal dementia (FTD) than among people with Alzheimer disease (AD) or healthy controls, according to a...
Tumor-Related Epilepsy Not Strong Prognostic Factor in Diffuse Glioma
WEDNESDAY, May 21, 2025 -- For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.